Immunological Gene Therapy Approaches for Malignant Melanoma

Skin Pharmacology and Physiology

Volumn 10, Issue 2, 1997, Pages 49-62

  Bonnekoh, Bernd ^a,b   Bickenbach, Jackie R ^a   Roop, Dennis R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Cancer; T lymphocytes; Tumor antigens; Tumor vaccine

Indexed keywords

CD8 ANTIGEN; CYTOKINE; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOTHERAPY; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR IMMUNOLOGY; TUMOR REJECTION;

CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; GENE THERAPY; HUMANS; IMMUNOTHERAPY; MELANOMA;

EID: 0030816345     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000211469     Document Type: Article

References (86)

1. Mulligan RC: The basic science of gene therapy. Science 1993:260: 926-932.
2. Morgan RA. Anderson WF: Human gene therapy. Annu Rev Biochcm 1993:62:191-217.
3. Greenhalgh DA, Rothnagel JA, Roop DR: Epidermis: An attractive target tissue for gene therapy. J Invest Dermatol 1994; 103:63S-69S.
4. Crystal RG: The gene as the drug. Nat Med 1995;1:15-17.
5. Johnson TM, Smith JW, Nelson BR, Chang A: Current therapy for cutaneous melanoma. J Am Acad Dermatol 1995;32:689-707.
6. Recombinant DNA Advisory Committee: Human gene marker/therapy clinical protocols. Hum Gene Thcr 1996:7:567-588.
7. Anderson WF: End-of-the-year potpourri - 1995. Hum Gene Ther 1995:6:1505-1506.
8. Han IR, Vile RG: Targeted therapy for malignant melanoma. Curr Opin Oncol 1994:6:221-225.
9. Pardoll DM: Tumor antigens. A new look for the 1990s. Nature 1994: 369:357-358.
10. Donawho C, Kripke ML: Photoimmunology of cutaneous melanoma; in Krutmann J, Elmets CA (eds): Photoimmunology. Oxford. Black-well, 1995, pp 119-127.
11. Bonnekoh B, Bickenbach JR, Roop DR: Gene therapy approaches for malignant melanoma - Treatment strategics and therapeutic potential of adenovirus-mediated gene transfer. Proc Am Acad Physicians (submitted).
12. Bonnekoh B, Greenhalgh DA, Bundman DS, Kosai K, Chen S-H, Finegold MJ, Krieg T, Woo SLC, Roop DR: Adenoviral-mediatcd herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma. J Invest Dermatol 1996:106: 1163-1168.
13. Bonnekoh B, Bickenbach JR, Roop DR: Immunological gene therapy approaches for malignant melanoma. 2. Preclinical studies and clinical strategics. Skin Pharmacol (in press).
14. Schreiber H: Tumor immunology: in Paul WE (ed): Fundamental Immunology, ed 3. New York, Raven Press. 1993. pp 1143-1178.
15. Hellstrom KE, lrie RF, Hellstrom I, Bystryn J-C, Morton DL, Wallack MK, Hoon DSB, Bash JA, Gupta RK, Hu S-L, Nizze AJ, Kahn M, Foshag LJ, Ferrone S: Melanoma vaccines; in Balch CM (ed): Cutaneous Melanoma. Philadelphia. Lippincott, 1992, pp 542-559.
16. Van den Eynde B, Brichard VG: New tumor antigens recognized by T cells. Curr Opin Immunol 1995:7: 674-681.
17. Huang AYC, Brude AT, Pardoll DM, Levitsky HI: Docs B7-I expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996;183:769-776.
18. Huang AYC, Golumbek P, Ahmad-zadeh M, Jaffec E, Pardoll D, Levitsky H: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-965.
19. Rock KL: A new foreign policy: MHC class I molecules monitor the outside of the world. Immunol Today 1996;17:131-137.
20. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990:60:397-403.
21. Rcstifo NP, Wunderlich JR: Biology of cellular immune responses: in De-Vita VT. Heilman S. Rosenberg SA (eds): Biology Therapy of Cancer, ed 2. Philadelphia, Lippincott, 1995, pp 3-37.
22. Dooley TP: Recent advances in cutaneous melanoma oncogenesis research. Oncol Res 1994:6:1-9.
23. Knudson AG: Mutation and cancer: A personal odyssey. Adv Cancer Res 1995;67:1-23.
24. Albino AP: Genes involved in melanoma susceptibility and progression. Curr Opin Oncol 1995:7:162-169.
25. Boon T, Cerottini J-C, Van den Eyndc B, Van der Bruggen P, Van Pei A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-365.
26. Coulie P, Lehmann F, Lethé B, Herman J, Lurquin C, Andrawiss M, Boon T: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sei USA 1995;192:7976-7980.
27. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-1284.
28. Houghton AN: Cancer antigens: Immune recognition of self and altered self. J Exp Med 1994;180:1-4.
29. Slingluff CL Jr, Hunt DF, Engelhard VF: Direct analysis of tumor-associated peptide antigens. Curr Opin Immunol 1994;6:733-740.
30. Kawakami Y, Robbins PF: Genes coding for tumor antigens recognized by T lymphocytes; in DeVita VT, Heilman S. Rosenberg SA (eds): Biology Therapy of Cancer, ed 2. Philadelphia. Lippincott. 1995. pp 53-64.
31. Storkus WJ, Lotze MT: Tumoranti-gens recognized by immune cells: in DeVita VT. Heilman S. Rosenberg SA (eds): Biology Therapy of Cancer, ed 2. Philadelphia, Lippincott. 1995. pp 64-77.
32. Van Pel A, Van Der Bruggen P. Coulie PG. Brichard VG, Lethe B, Van den Eynde B, Uyttenhove C. Renauld J-C. Boon T: Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995;145:229-250.
33. Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugier B, Wölfel T, Boon T, Lethe B: A tyrosinase nona-peptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lympho-cvtes. EurJ Immunol 1996:26:224-230.
34. Van der Bruggen P, Traversari C, Chomez P, Lurquin C. De Plaen E, Van den Eynde B. Knuth A. Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-1647.
35. Brichard V, Van Pei A, Wölfel T, Wölfel C, De Plaen E, Lethe B. Coulie P. Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993:178:489-495.
36. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA: Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sei USA 1994:91: 9461-9465.
37. Skipper JCA, Hendrickson RC, Gulden PH, Brichard V, Van Pci A, Chen Y, Shabanowitz J, Wölfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH: An HLA-A2-re-strictcd tyrosinase antigen on melanoma cells results from posttransla-tional modification and suggests a novel pathway for processing of membrane proteins. .1 Exp Med 1996;183:527-534.
38. Gansbacher B: A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. Hum Gene Ther 1992:3:677-690.
39. Osanto S: Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma. Hum Gene Ther 1993:4:323-330.
40. Jaffee EM, Hurwitz H, Pardoll DM: Gene modification of tumors: in De-Vita VT. Heilman S. Rosenberg SA (eds): Biology Therapy of Cancer, ed 2. Philadelphia. Lippincott, 1995. pp 774-783.
41. Rankin EM: Scientific aspects of gene therapy in melanoma. Curr Opin Oncol 1995;7:192-196.
42. Young JW, Inaba K: Dendritic cells as adjuvants for class 1 major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996:183:7-11.
43. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr: Peptide-pulsed dendritic cells induce antigen-specific. CTL-mediated protective tumor immunity. J Exp Med 1996:183:283-287.
44. Zitvogel L, Mayordomo JI, Tjandra-wan T, DcLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
45. Alijagic S, Moller P, Artuc M, Jur-govsky K, Czarnetzki BM, Schadcn-dorf D: Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur J Immunol 1995;25:3100-3107.
46. Guo Y, Wu M, Chen H, Wang X, Liu G. Li G, Ma J. Sy M-S: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994:263:518-520.
47. McClain K: Immunodeficiency secondary to infiltrative disease and malignancy; in Rich RR (ed): Clinical Immunology. Principles and Practice. St Louis, Mosbv. 1996. pp 817-823.
48. Morisaki T, Morton DL, Uchiyama A, Yuzuki D, Barth A, Hoon DSB: Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma. Cancer Immunol Immunother 1994;39:172-178.
49. Gansbacher B, Zier K, Cronin K, Hantzopoulos PA, Bouchard B, Houghton A, Gilboa H, Golde D: Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-y in irradiated human melanoma cells. Blood 1992: 80:2817-2825.
50. Scnsi M, Parmiani G: Analysis of TCR usage in human tumors: A new tool for assessing tumor-specific immune responses. Immunol Today 1995:16:588-595.
51. Berke G: The CTL's kiss of death. Cell 1995;81:9-12.
52. Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM. Frelinger JG: Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-depcndcnt mechanism. Cancer Res 1993:53:2112-2117.
53. Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner E, Buschic M, Maass G, Payer E, Stingl G, Bim-stiel ML: Elicitation of a systemic and protective anti-melanoma immune response by an lL-2-bascd vaccine: Assessment of critical cellular and molecular parameters. J Immunol 1995;154:3406-3419.
54. Octtgen HF, Old LJ: The history of cancer immunotherapy; in DeVita VT. Heilman S. Rosenberg SA (cds): Biologic Therapy of Cancer. Philadelphia. Lippincott. 1991. pp 87-119.
55. Law LW, Vieira WD, Hearing VJ, Gersten DM: Further studies of the therapeutic effects of murine melanoma-specific monoclonal antibodies. Biochim Biophys Acta 1994: 1226:105-109.
56. Merimsky O, Shoenfeld Y, Chai-tchik S, Yecheskel G, Fishman P: Antigens and antibodies in malignant melanoma. Tumor Biol 1994; 15:188-202.
57. Ferrone S, Chu TM, Hellstrom I, Hellstrom KE: Tumor antigens recognized by monoclonal antibodies: in DeVita VT. Hellntan S, Rosenberg SA (eds): Biology Therapy of Cancer, ed 2. Philadelphia, Lippincott, 1995, pp 77-86.
58. Eisenthal A, Cameron RB, Rosenberg SA: Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-a and its antitumor efficacy against established B16 melanoma liver mctastascs when combined with specific anti-B16 monoclonal antibody. J Immunol 1990:144: 4463-4471.
59. Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 1992;10:180-199.
60. Primus FJ, Finch MD, Wetzel SA. Masci AM, Seldom J. Kashmir SVS: Monoclonal antibody gene transfer. Ann NY Acad Sci 1994:716:154-166.
61. Bcrd D, Maguire HC, McCue P, Mastrangclo MJ: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 1990:8:1858-1867.
62. Wallack MK, Sivanandhant M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty LE. Richards JM, Bartolucci AA. Rosen L: A phase 111 randomized, double-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage 11 melanoma. Cancer 1995;75:34-42.
63. Blankcnstcin T: Increasing tumor immunogenicity by genetic modification. Eur J Cancer 1994;30A: 1182-1187.
64. Ferrone S, Marineóla FM: Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995:16: 487-494.
65. Restifo NP, Marineóla FM, Kawa-kami Y, Taubcnbcrger J, Yannelli JR, Rosenberg SA: Loss of functional betai-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996;88:100-108.
66. Bruyns C, Gérard C, Velu T: Cancer escape from immune surveillance: How can it be overcome by gene transfer? Eur J Cancer 1994;30A: 1176-1181.
67. Pardoll DM, Beckcrleg AM: Exposing the immunology of naked DNA vaccines. Immunity 1995:3:165-169.
68. Tepper RI, Mule JJ: Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994:5:153-164.
69. Zier KS, Gansbacher B: IL-2 gene therapy of solid tumors: An approach for the prevention of signal transduction defects in T cells. J Mol Med 1996;74:127-134.
70. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995:13:399-415.
71. Berkelhammcr J, Oxenhandler RW, Hook RR, Hennessy JM: Development of a new melanoma model in C57BL/6 mice. Cancer Res 1982;42: 3157-3163.
72. Wahl WL, Strome SE, Nabel GJ, Plautz GE, Cameron MJ, San H, Fox BA, Shu S, Chang AE: Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene. J Immunother 1995;17:1-11.
73. Starosclsky AH, Pathak S, Chema-jovsky Y, Tucker SL, Fidler IJ: Predominance of the metastatic phenotype in somatic cell hybrids of the K-1735 murine melanoma. Cancer Res 1991;51:6292-6298.
74. Allison JP, Hurwitz AA, Leach DR: Manipulation of costimulatory signals to enhance antitumor T-cell response. CurrOpin Immunol 1995:7: 682-686.
75. Rigel DS: Epidemiology and prognostic factors in malignant melanoma. Ann Plast Surg 1992;28:7-8.
76. Marks R: An overview of skin cancers - Incidence and causation. Cancer 1995;75(suppl):607-612.
77. Prehn RT: The paradoxical association of regression with a poor prognosis in melanoma contrasted with a good prognosis in kcratoacanthoma. Cancer Res 1996:56:937-940.
78. Mukherji B, Chakraborty NG: Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 1995;7:175-184.
79. Merimsky O, Shoenfeld Y, Yeches-kcl G, Chaitchik S, Azizi E, Fishman P: Vitiligo- and melanoma-associated hypopigmentation: A similar appearance but a different mechanism. Curr Immunol Immunother 1994: 38:411-416.
80. Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW, Dutcher JP, Gaynor ER. Weiss GR: Phase II studies of recombinant human in-terleukin-4 in advanced renal cancer and malignant melanoma. J Immunother 1994;15:147-153.
81. Stingl G: Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. Hum Gene Ther 1996;7:551-563.
82. Sumiami Y, Elder EM, Lotze MT, Whiteside TL: In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother 1995: 17:238-248.
83. Zhai Y, Yang KC. Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE. Rosenberg SA: Antigen-specific tumor vaccines - Development and characterization of recombinant adenoviruses encoding MARTI orgplOO for cancer therapy. J Immunol 1996; 156:700-710.
84. Nabel GJ, Nabel EG, Yang Z-Y, Fox B. Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sei USA 1993;90:11307-11311.
85. Ettinghausen SE, Rosenberg SA: Immunotherapy and gene therapy of cancer. AdvSurg 1995;28:223-254.
86. Chang AE: Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum Gene Ther 1996:7:773-792.